JDG

公司名称：Judges Scientific plc

主要经营地：英国

详细生意模式：连续并购专家，2005年起已收购23家利基科学仪器公司(材料科学53%收入、真空47%)。分散式运营，4-6倍EBIT收购价、16-25% ROI、买入后不干预。20年收入CAGR 18%、调整EBIT CAGR 22%，从2003 IPO至今100倍增长。

护城河：🟢强：资本配置纪律与founder原主人翻身/保留机制、利基产品定价权、并购目标库充足(1000+公司)

估值水平：PE 10.5x, EV/EBITDA 10.2x

EV/Market Cap：EV $330M / MC $280M

网络观点：作者强调20年CAGR(收入18%、EBIT 22%)与100倍2003 IPO回报率，当前虽跌69%但仍40倍。严纪律M&A、资本轻装、护城河深。联邦研究经费削减为逆风。

AI观点：优质企业但估值反映多数优点。搜索最新：JDG在2026年4月2日公布财报，继续维持23家并购组合与海外扩张计划。风险是联邦研究经费削减持续恶化、美国经济衰退冲击学术/工业科研投资、并购成本通胀下难维持4-6x EBIT。机会是如果经济恢复+利率下降，并购交易流活跃。经验丰富的CEO团队与founder-friendly文化是竞争优势。结论：优质管理与长期track record无疑，但当前估值已合理反映品质，不提供显著安全边际，暂时观望

Judges Scientific (JDG) is a serial acquirer of small scientific instrument businesses in the UK. The company has a 20-year track record of delivering 25% annual shareholder returns. JDG focuses on acquiring niche market leaders with strong pricing power and little competition. The company's hands-off approach and integrity allow it to acquire businesses at an average of 4.8x EBIT. Management is heavily invested in the company, with the CEO's holdings worth around 200x his salary. Despite its success, the company remains under-followed by institutional investors. Key risks include the potential retirement of the 76-year-old CEO, though a succession plan appears to be in place.

Judges Scientific is a UK-based serial acquirer of niche scientific instrument businesses, operating a decentralized buy-and-build strategy. The company has a strong track record of acquiring and growing businesses, with a 5-year revenue CAGR of 10.8% and a 5-year FCF CAGR of 12.0%. The company is led by its founder and CEO, David Cicurel, who owns 9.2% of the company. The article suggests that the stock is currently trading at an attractive valuation, with a FCF yield of 4.4% compared to its 5-year average of 3.2%. The author expects future EBIT and FCF growth of 10-16% per year. The main risks are identified as macroeconomic uncertainty, potential acquisition missteps, and CEO succession.